MELA Sciences, Inc. announced the resignation of Richard I. Steinhart, SVP Finance and Chief Financial Officer, effective December 31, 2013. Mr. Steinhart has served as MELA's CFO since 2006. Rose Crane, MELA's CEO, will handle the CFO responsibilities on an interim basis with the assistance of the company's controller.

Due to other professional commitments and a desire to streamline the Board to better reflect the Company's current size, three of MELA's nine directors have resigned from the Board effective year-end 2013. The departing directors are pharmaceutical marketing executive Anne Egger, crisis communications consultant Mark Fabiani and Mindy Meads, recently named CEO of specialty retailer Calypso St. Barth.

To bolster its commitment to dermatologists as well as to secure added medical device management expertise, MELA has appointed healthcare executive and venture capitalist, Jeffrey F. O'Donnell to the Board effective January 1, 2014, bringing the number of MELA directors to seven. Mr. O'Donnell is Managing Director of BioStar Ventures. Mr. O'Donnell is currently on the Boards of CD Diagnostics and BioSig Technology and serves as Executive Chairman of Trice Orthopedics, Inc.